Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes
NEW YORK--(BUSINESS WIRE)--Kallyope, Inc., a clinical stage biotechnology company discovering and developing novel, oral small-molecule therapeutics for diseases with high unmet need, today announced the appointment of Franz Humer, Ph.D., a distinguished global industry leader in the life sciences, finance, and investment, as the new chair of its board of directors.
NEW YORK--(BUSINESS WIRE)--Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the promotion of Shirly Pinto, Ph.D., to Chief Scientific Officer and the appointments of Jiajun Liu, Ph.D., as Vice President and Head of Biometrics and Michael Crutchlow, M.D., as Vice President and Head of Translational Medicine.
Collaboration is part of Sosei Heptares’ Target Identification and Validation (TIV) strategy to leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key...
Kallyope Inc., a company leveraging connections between the gut microbiome and brain to develop new medicines for diabetes, obesity and other diseases, has raised $236 million in series D financing to support its work. Readouts of early clinical data for its most advanced programs, phase I small molecules for metabolic disease and gut barrier conditions, will start to arrive later this year, company CEO and President Jay Galeota told BioWorld.